Skip to main content
18 search results for:

Vemurafenib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 09-07-2019 | Non-small-cell lung cancer | News | Article

    Vemurafenib monotherapy has potential for BRAF-mutated NSCLC

    Single-agent vemurafenib has demonstrated promising antitumor activity against non-small-cell lung cancer harboring BRAF V600E mutations in the VE-BASKET trial.

  2. 16-08-2017 | Melanoma | News | Article

    Final BRIM-3 data confirm vemurafenib survival benefit over dacarbazine

    Final data from the BRIM-3 trial show that overall survival remains significantly better with vemurafenib than with dacarbazine when given to treatment-naïve patients with BRAF V600 mutation–positive metastatic melanoma.

  3. 21-03-2018 | Targeted therapy | Article

    Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

    Dummer R et al.  Lancet Oncol 2018; 19(5): 603-615. doi:10.1016/S1470-2045(18)30142-6

  4. 30-09-2017 | Metastatic melanoma | Article

    Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

    Chapman PB et al.  Ann Oncol  2017; 28(10): 2581-2587. doi:10.1093/annonc/mdx339

  5. 26-05-2022 | Non-small-cell lung cancer | News | Article
    News in brief

    Antibiotics tied to poor NSCLC, melanoma TKI outcomes

    The analysis included data on 168 patients (89 with NSCLC, 79 with melanoma) who received first-line TKI therapy with dabrafenib, vemurafenib, gefitinib, afatinib, or erlotinib between January 2015 and April 2017 at The Christie NHS Foundation Trust.

  6. 23-04-2018 | Melanoma | News | Article

    Encorafenib–binimetinib a new option for BRAF-mutated melanoma

    The combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib has favorable efficacy and tolerability relative to either encorafenib or vemurafenib alone in patients with advanced melanoma harboring BRAF mutations, phase III trial findings indicate. Read the accompanying comment by Eva Muñoz Couselo

  7. 18-06-2018 | Melanoma | ASCO 2018 | Article
    News in brief

    COLUMBUS OS data favor encorafenib–binimetinib for advanced BRAF-mutated melanoma

    Presenting the findings at the ASCO Annual Meeting 2018 , Reinhard Dummer (University Hospital Zürich, Switzerland) explained that the combination previously showed a “clear advantage” with regard to progression-free survival relative to vemurafenib.

  8. 23-08-2018 | Targeted therapy | News | Article

    New molecular target classification system could aid treatment decision making

    Tier III is for targets where clinical benefit has been demonstrated in other tumor types, for example B-Raf enzyme inhibition with vemurafenib, which significantly extends survival in patients with metastatic melanomas harboring the BRAF V600E mutation but has variable activity in other tumors.

  9. play
    26-09-2017 | ESMO 2017 | Video

    ESMO 2017: BRIM8 trial findings

    Presenter Karl Lewis outlines the findings for adjuvant vemurafenib versus placebo in patients at high risk of recurrence after resection of BRAF V600+ advanced or metastatic melanoma.

  10. 23-04-2018 | Article

    Expert comment

    A press release published in February 2018 by Array BioPharma Inc and Pierre Fabre announced that the combination of encorafenib plus binimetinib shows a median OS of 33.6 months for patients treated with the combination, compared with 16.9 months for patients treated with vemurafenib as a monotherapy. 

  11. 09-11-2017 | FDA | News | Article
    approvalsWatch

    FDA approves first Erdheim-Chester disease therapy

    Vemurafenib is recommended at a dose of 960 mg twice daily taken with or without food.

  12. 30-11-2017 | Melanoma | News | Article
    News in brief

    Checkpoint inhibitors, targeted therapies boost advanced melanoma OS in USA

    The CTLA-4 inhibitor ipilimumab and the BRAF blocker vemurafenib received US FDA approval in 2011, and this analysis of national-level outcomes showed that OS was significantly better for the 3586 patients diagnosed in 2011 and 2012 than for the 3352 patients who received their diagnosis in 2009–2010 and the 4869 diagnosed in 2004–2008, with corresponding hazard ratios of 0.89 and 0.85.

  13. 11-11-2016 | Treatment | Article

    Combinatorial immunotherapy for melanoma

    In November of 2015, the FDA approved the combination of vemurafenib plus cobimetinib based on a pivotal phase III trial versus vemurafenib plus placebo that included 495 patients with previously untreated, unresectable, locally advanced or metastatic BRAF V600 mutation-positive melanoma.

  14. 17-08-2016 | Hematologic cancers | Article

    Genomic complexity of multiple myeloma and its clinical implications

    A report published in 2013 describes a durable response (>7 months at the time of reporting) of a patient harbouring the activating mutation of BRAF V600E to the mutation-specific BRAF inhibitor vemurafenib 110 .

  15. 04-01-2016 | Treatment | Article

    Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity

    NCT02077959, phase I/II Lenalidomide Small molecules and signaling pathway inhibitors Vemurafenib BRAF V600E i.v.

  16. 24-07-2015 | Treatment | Article

    Evolving synergistic combinations of targeted immunotherapies to combat cancer

    As ipilimumab has a half-life of 15 days, administration of vemurafenib within 4 weeks of the last dose of ipilimumab can be considered combination therapy.

  17. 25-07-2015 | Breast cancer | Article

    Precision medicine for metastatic breast cancer—limitations and solutions

    These trials include the evaluation of vemurafenib in BRAF V600E -positive cancers (NCT01524978) 86  or crizotinib in patients with molecular alterations in  ALK, MET  or  ROS  genes (NCT02034981). 87  The umbrella trials assess the effect of different drugs in different molecular alterations either in one or several tumours.

  18. 23-04-2018 | Non-small-cell lung cancer | Article

    BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall

    Leonetti A et al. Cancer Treat Rev  2018; 66: 82-94. doi:10.1016/j.ctrv.2018.04.006

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.